Recent studies using adult glioblastoma models demonstrated that combinatorial treatment with TMZ and the PI3K/mTOR inhibitors voxtalisib or NVP-BEZ235 significantly reduced tumour growth rates and prolonged median survival of tumour-bearing mice [35, 55]. Here, PIK3CA is linked to glioblastoma.